Non-linear association of serum 25-hydroxyvitamin D with urinary albumin excretion rate in normoalbuminuric subjects

Yun Jung Oh1,2†, Rae Woong Park3,4†, Dukyong Yoon4, Myounghiee Kim5, Seung Seok Han3, Hye Ryoun Jang6, Hyosang Kim7, Nam Ju Heo8, Su-Kil Park7, Hajeong Lee1, Kwon Wook Joo1, Chun-Soo Lim1, Yon Su Kim1 and Dong Ki Kim1*

Abstract

Background: Vitamin D deficiencies and increases in urinary albumin excretion (UAE) are both important and potentially related health problems; however, the nature of their relationship has not been established in normoalbuminuric subjects.

Methods: We obtained data from 14,594 normoalbuminuric Korean adults who underwent voluntary health screenings. We used a generalized additive model to examine the threshold level for relationship between serum 25-hydroxyvitamin D [25(OH)D] and urinary-albumin creatinine ratio (UACR) levels. We conducted multivariate logistic regression for high-normal UAE (UACR, 10–29 mg/g), according to various categories of vitamin D status.

Results: The generalized additive model confirmed a non-linear relationship between serum 25(OH)D and UACR levels, and the threshold concentration of 25(OH)D was 8.0 ng/mL after multivariate adjustment. Comparing subjects who fell into the lowest category of serum 25(OH)D levels with subjects who were in the reference range (the highest category), we observed that the multivariate adjusted odds ratio (OR) for high-normal UAE was significantly increased, regardless of the criteria used to categorize vitamin D levels: OR of the 1st quartile over the 4th quartile, 1.20 (95% CI, 1.04-1.39); OR of the 1.0-4.9th percentile over the 50-100th percentile, 1.56 (95% CI, 1.25-1.93); and OR of vitamin D deficiency group over vitamin D sufficiency group, 1.28 (95% CI, 1.08-1.52).

Conclusions: We demonstrated that there was an inverse relationship between serum 25(OH)D less than 8.0 ng/mL and UACR in normoalbuminuric subjects, suggesting that severe vitamin D deficiency could cause an increase in UAE in subjects with normoalbuminuria.

Keywords: Epidemiology, Low-grade albuminuria, Threshold, Vitamin D deficiency

Background

Albuminuria is not only an independent prognostic marker for kidney disease, but it is also an established predictor of cardiovascular disease and all-cause mortality [1-3]. However, there has been considerable debate over the threshold level of urinary albumin excretion (UAE) that predicts adverse clinical outcomes. Recently, meta-analyses of general- and high-risk population cohorts have demonstrated that increased UAE, even within the normoalbuminuric range, especially a urinary albumin-creatinine ratio (UACR) of 10–29 mg/g, is an independent predictor of cardiovascular disease and all-cause mortality [4,5]. These noteworthy reports on the prognostic significance of the higher range of normoalbuminuria have challenged the previous definition of normoalbuminuria. Furthermore, given the high prevalence of the greater range of normoalbuminuria in the general population [6], we believe that exploring its risk factors might have important public health and clinical implications.

Vitamin D deficiency is an important public health issue because of its association with numerous adverse
conditions [7]. The association of vitamin D with albuminuria has been suggested; however, most of these studies have been limited to subjects with chronic kidney disease or diabetes, which are susceptible to albuminuria [8-12]. Recently, general population studies have shown that vitamin D deficiency was associated with prevalent microalbuminuria and that vitamin D deficiency posed an increased risk of de novo microalbuminuria [13,14]. However, these studies did not consider high-normal UAE as a separate outcome variable, despite its obvious clinical significance and high prevalence. Moreover, previous studies did not consider a possible non-linear relationship between 25-hydroxyvitamin D [25 (OH)D] and UACR levels, although recent large-scale studies have suggested a non-linear relationship between the risks of various clinical conditions and serum 25(OH)D levels [15-20].

Based on previous findings regarding the association between vitamin D and albuminuria, we postulated that low vitamin D levels might be a potential risk factor for high-normal UAE. In the present study, we examined the relationship between serum 25(OH)D and UACR levels in a large number of subjects who underwent voluntary health screenings. We aimed to estimate the threshold level of serum 25(OH)D less than which UAE would begin to increase.

Methods

Study population
We conducted this study using data from subjects who underwent voluntary health screenings at three university-affiliated hospitals, including Seoul National University Hospital (Seoul, Korea), Samsung Medical Center (Seoul, Korea), and Asan Medical Center (Seoul, Korea), between January 2008 and March 2012. Initially, we recruited a total of 16,870 subjects, who were aged ≥20 years old, and they underwent measurements of serum 25(OH)D and UACR. From that group, we excluded 2,276 subjects with outlying values of serum 25(OH)D (>125 ng/mL, N = 3) or UACR ≥30 mg/g (N = 2,276). A total of 14,594 participants were included in the study analysis. This study was approved by the institutional review boards of the three hospitals and performed in accordance with the principle of Helsinki Declaration. The IRBs approved waiver of the requirement for obtaining written informed consent because this study was conducted by retrospective chart review and presented no more than minimal risk to participants.

Normalization of laboratory tests
The quantile normalization method [21,22] was applied to combine the laboratory test results of the three participating institutions, using a Java programming tool (Eclipse, version 3.7.1, IBM, Riverton, NJ). The quantile normalization method is a technique that redistributes values of datasets to have same statistical properties. The quantile normalization makes datasets have identical distribution by averaging values at the same ranking in each dataset. Each datum of a distribution was sorted in ascending order, and the data in the same rank were averaged together. The averaged value was set as the new normalized value. To determine the reference range, all of the laboratory test results were subdivided by reference range, and subsequently, each stratum was independently normalized.

Vitamin D and albuminuria
We measured serum 25(OH)D levels at a single baseline visit. Serum 25(OH)D levels were measured using a radioimmunoassay kit (BIOSOURCE, Brussels, Belgium) and a gamma-counter (COBRA 5010 Series Quantum, PACKARD, Meriden, CT) at two medical centers (Seoul National University Hospital and Asan Medical Center), while at Samsung Medical Center, these levels were measured by liquid chromatography-tandem mass spectrometry assay, using a mass spectrometer (6460 Triple Quadrupole mass spectrometer, Agilent, Santa Clara, CA). We categorized serum 25(OH)D levels by quartiles. We also divided the subjects into four groups by percentile categories of 25(OH)D concentrations (1.0-4.9th; 5.0-24.9th; 25.0-49.9th and 50.0-100.0th percentile). Additionally, we assigned categories of serum 25(OH)D levels according to generally used clinical cut-off points (vitamin D deficiency, <15.0 ng/mL; insufficiency, 15.0-29.9 ng/mL; sufficiency, ≥30 ng/mL) [23,24]. For an assessment for UACR, urine albumin and creatinine were measured from a single random voided urine sample. Urine albumin levels were measured by immunoturbimetric assay (ALBT2, Roche, Basel, Switzerland). Urine creatinine levels were measured using the Jaffe method (CREJ2, Roche). We classified the status of UAE into two groups according to UACR levels. Normal UAE was defined as UACR <10 mg/g and high-normal UAE was defined as UACR 10–29 mg/g.

Study variables
Demographic and clinical data included age, sex, body mass index (BMI), blood pressure, blood and urine chemistry analysis, and medication history, including vitamin D supplements and renin angiotensin system (RAS) blockers. We classified time points into four seasons as follows; spring (March to May); summer (June to August); autumn (September to November); and winter (December to February). Additionally, we assembled information about medical co-morbidities. Hypertension was defined as blood pressure ≥140/90 mmHg; a reported history of hypertension or those individuals who received antihypertensive medications were documented. Diabetes was
defined as a reported history of diabetes, including individuals who received oral hypoglycemic agents or insulin. The estimated glomerular filtration rate (eGFR) was calculated using four-variable Modification of Diet in Renal Disease equation [25].

**Statistical analysis**

All of the analyses and calculations were performed using SPSS Statistics software (version 19.0, Chicago, IL) and R software, version 2.15.1, with the mgcv package (The Comprehensive R Archive Network: http://cran.r-project.org). Continuous variables with normal distributions are presented as the means ± SDs and were compared using Student’s t-test. Non-normally distributed continuous variables are expressed as the medians (25-75% interquartile ranges) and were compared using the Mann–Whitney U-test. Categorical variables are expressed as frequencies or percentages, and comparison between groups was performed using the chi-squared test for dichotomized variables. We conducted logistic regression analysis to identify the independent effects of serum 25(OH)D levels on the risk of high-normal UAE. Two-sided P values were reported, and statistical significance was defined as P < 0.05.

A Gaussian model was adapted to evaluate the effects of serum 25(OH)D levels on UACR levels. To investigate the continuous relationship between serum 25(OH)D and UACR levels, we used generalized additive models (GAMs) with a smoothing function for UACR levels [26]. In addition to univariate analysis, we performed multivariate analysis, constructing multiple models adjusted for relevant covariates in a stepwise manner. To estimate the threshold of the serum 25(OH)D concentration for each model, we first selected the serum 25(OH)D range and fitted the GAM to quantify the relationship between serum 25(OH)D and UACR levels. Akaike’s information criterion (AIC) was used to determine a primary measurement of model fit; a lower value of AIC indicated a better model fit. The threshold of serum 25(OH)D was chosen, based on the best fit determined by AIC among the models, with threshold values that differed in 0.2-increments. We plotted the optimal criterion on the GAM model. Predicted probability was calculated from the multivariate logistic regression model. We presented curves of predicted probability and 95% CIs using the loweress regression.

**Results**

**Clinical characteristics**

A total of 14,594 subjects were included in this study. The mean age was 54 years old, and 64.7% of participants were male. The seasonal distribution of the examination was nearly even across the entire examination period. The serum 25(OH)D levels were normally distributed (Figure 1A). However, UACR showed a highly skewed distribution (Figure 1B). Table 1 presents the clinical characteristics of study population. The mean serum 25(OH)D and eGFR levels were 20.4 ± 8.4 ng/mL and 85.8 mL/min/1.73 m², respectively, and the median value of UACR was 4.3 mg/g. Overall, 28.0% of participants had vitamin D deficiency. The serum 25(OH)D level was lower in high-normal UAE than in normal UAE. The hemoglobin level was also lower in high-normal UAE compared to normal UAE; however, the serum albumin and eGFR levels were not significantly different between the groups. Additionally, the prevalence of diabetes and hypertension in subjects with high-normal UAE was significantly higher compared to those with normal UAE.

**Associations of serum 25(OH)D levels with UACR and threshold 25(OH)D values for their associations with albuminuria**

We explored the continuous relationship between serum 25(OH)D and UACR levels. As shown in the loweress line of Figure 2, there was no specific association of serum
25(OH)D with UACR levels until 25(OH)D levels decreased to approximately 15 ng/mL; however, the UACR level increased with decreasing serum 25(OH)D to approximately less than 15 ng/mL of serum 25(OH)D level. Based on the findings, we investigated the non-linear relationship between serum 25(OH)D and UACR levels, and we estimated the threshold level of serum 25(OH)D less than which UACR levels started to increase. To estimate the threshold, we used GAM, and we made adjustments for relevant covariates, including age, sex, season, BMI, hemoglobin, eGFR, hypertension, diabetes, use of vitamin D supplements and RAS blockers, serum albumin, calcium, phosphorus, high-density lipoprotein (HDL) cholesterol, triglycerides, and high-sensitivity-C-reactive protein (hs-CRP), in a stepwise manner. In each model, we used the AIC to assess model fit, and we finally selected the best-adapted model for estimating the threshold. Figure 3 shows the unadjusted, age-, sex-, and season-adjusted, and multivariate-adjusted GAM plots used to identify the threshold level of 25(OH)D that predicted changes in UACR levels. In the best adapted model, adjusted for potential confounding factors, 8.0 ng/mL of serum 25(OH)D had the lowest AIC value: the difference from the mean UACR began to increase as the serum 25(OH)D level decreased to less than the threshold level of 8.0 ng/mL.

Risk of high-normal UAE according to the serum 25(OH)D levels
We investigated whether serum 25(OH)D levels were significantly associated with the prevalence of high-normal UAE, using a logistic regression model. A stepwise increase in the prevalence of high-normal UAE was observed with decreasing serum 25(OH)D levels, which were indicated by quartiles, percentiles, and clinical categories (Figure 4). However, we observed a significant increase in high-normal UAE in only the lowest category of serum 25(OH)D, which indicated very low

Table 1 Clinical characteristics of study population

|   | Total (N = 14,594) | UACR < 10 mg/g (N = 12,170) | UACR 10–29 mg/g (N = 2,424) | P value | Serum 25(OH)D ≥15 mg/g (N = 10,505) | Serum 25(OH)D <15 mg/g (N = 4,089) | P value |
|---|-------------------|-------------------------------|-----------------------------|---------|-----------------------------------|-----------------------------------|---------|
| Age (years) | 54.0 ± 9.0 | 53.4 ± 8.5 | 56.6 ± 9.8 | <0.01 | 54.3 ± 8.7 | 53.0 ± 9.0 | <0.01 |
| Male (N/%) | 9,441/64.7 | 8,168/67.1 | 1,276/52.5 | <0.01 | 7,237/68.9 | 2,204/53.9 | <0.01 |
| Season (N/%) | | | | | | | |
| Spring | 3,813/26.1 | 3,195/26.3 | 619/25.5 | 2,550/24.3 | 1,263/30.9 |
| Summer | 3,772/25.8 | 3,217/26.4 | 557/22.9 | 3,004/28.6 | 768/18.8 |
| Autumn | 3,620/24.8 | 3,010/24.7 | 611/25.2 | 2,853/27.2 | 767/18.8 |
| Winter | 3,389/23.2 | 2,748/22.6 | 642/26.4 | 2,098/20.0 | 1,291/31.6 |
| BMI | 24.39 ± 2.97 | 24.36 ± 2.90 | 24.53 ± 3.25 | 24.54 ± 2.90 | 24.01 ± 3.12 |
| 25(OH)D (ng/mL) | 20.4 ± 8.4 | 20.5 ± 8.4 | 20.0 ± 8.7 | 23.8 ± 7.4 | 11.7 ± 2.3 |
| UACR (mg/g) | 4.3 (2.5-7.7) | 3.6 (2.2-5.6) | 14.5 (11.9-19.1) | 14.6 ± 1.5 | 14.2 ± 1.6 |
| Hemoglobin (g/dL) | 14.5 ± 1.5 | 14.5 ± 1.5 | 14.2 ± 1.7 | 14.6 ± 1.5 | 14.2 ± 1.6 |
| Serum albumin (g/dL) | 4.4 ± 0.3 | 4.4 ± 0.3 | 4.4 ± 0.3 | 4.4 ± 0.3 | 4.4 ± 0.3 |
| Serum calcium (mg/dL) | 9.1 ± 0.4 | 9.0 ± 0.4 | 9.1 ± 0.4 | 9.1 ± 0.4 | 9.0 ± 0.4 |
| Serum phosphorus (mg/dL) | 3.5 ± 0.5 | 3.4 ± 0.5 | 3.5 ± 0.6 | 3.4 ± 0.5 | 3.5 ± 0.5 |
| hs-CRP (mg/dL) | 0.10 (0.00-0.10) | 0.10 (0.00-0.10) | 0.10 (0.00-0.20) | 0.10 (0.00-0.10) | 0.003 |
| Total cholesterol | 189 ± 35 | 189 ± 34 | 188 ± 39 | 190 ± 35 | 187 ± 36 |
| LDL-cholesterol | 121 ± 33 | 122 ± 32 | 120 ± 35 | 122 ± 33 | 120 ± 33 |
| HDL-cholesterol | 54 ± 13 | 54 ± 13 | 54 ± 14 | 54 ± 13 | 54 ± 13 |
| Triglyceride | 120 ± 74 | 119 ± 72 | 126 ± 82 | 122 ± 74 | 116 ± 74 |
| eGFR (mL/min/1.73 m²) | 85.8 ± 18.6 | 86.3 ± 17.3 | 86.7 ± 20.7 | 85.1 ± 17.4 | 89.4 ± 18.7 |
| Diabetes | 1,348/9.2 | 1,001/8.2 | 348/14.3 | 972/9.3 | 376/9.2 |
| Hypertension | 1,721/11.8 | 1,289/10.6 | 435/17.9 | 1,279/12.2 | 442/10.8 |
| RAS blocker | 1,013/6.9 | 765/6.3 | 250/10.3 | 755/7.2 | 258/6.3 |
| Vitamin D supplementation | 1,012/6.9 | 766/6.8 | 247/11.0 | 700/7.2 | 312/8.3 |

Abbreviations: 25(OH)D 25-hydroxyvitamin D, BMI body mass index, UACR urine albumin-creatinine ratio, hs-CRP high sensitivity-C-reactive protein, LDL low density lipoprotein, HDL how density lipoprotein, eGFR estimated glomerular filtration rate, RAS renin angiotensin system. Variables are expressed as the means ± SD or median (25th,75th percentiles).
vitamin D levels. Adjusting for multiple covariates, including age, sex, season, BMI, hemoglobin, eGFR, hypertension, diabetes, use of vitamin D supplements and RAS blockers, serum albumin, calcium, phosphorus, HDL cholesterol, triglycerides, and hs-CRP, all of the lowest categories of serum 25(OH)D levels, by quartile, percentile, and clinical category, were significantly associated with the risk of high-normal UAE. The OR of the lowest quartile over the highest quartile was 1.20 (95% CI, 1.04-1.39), the OR of the 1.0-4.9% over the 50.0-100.0% was 1.56 (95% CI, 1.25-1.93), and the OR of subjects with vitamin D deficiency over those with vitamin D sufficiency was 1.28 (95% CI, 1.08-1.52). Stratified analyses according to the presence or absence of diabetes showed similar patterns. In the subjects with diabetes, multivariate-adjusted odds of high-normal UAE were significantly higher in the lowest serum 25(OH)D quartile and in vitamin D deficiency defined by the clinical category. The risk of high-normal UAE in non-diabetic subjects with vitamin D deficiency was also significantly higher than that in non-diabetic subjects with vitamin D sufficiency (Additional file 1: Figure S1).

Figure 5 presents the predicted probability of high-normal UAE based on serum 25(OH)D levels. After full adjustments for age, sex, season, BMI, hemoglobin, eGFR, hypertension, diabetes, use of vitamin D supplements and RAS blockers, serum albumin, calcium, phosphorus, HDL cholesterol, triglycerides, and hs-CRP, the predicted probability of high-normal UAE increased non-linearly with decreasing serum 25(OH)D levels, particularly at approximately the threshold levels of serum 25(OH)D.

Discussion
In the present study, conducted in a large number of health-screening subjects, we demonstrated a non-linear relationship between serum 25(OH)D and UACR levels in normoalbuminuric subjects, and we identified the threshold level of serum 25(OH)D levels, by quartile, percentile, and clinical category, that predicted an increase in UAE, independent of confounding variables. Because the serum 25(OH)D threshold was lower than the generally accepted lower limit of the normal range,
the present study indicates that severe vitamin D deficiency could cause an increase in UAE. Additionally, we demonstrated that the risk of high-normal UAE (UACR 10–29 mg/g) increased as the serum 25(OH)D level decreased; however, the trend was not linear. Thus, the present study raises the important issue that vitamin D could be a potential therapeutic option for the management or prevention of increases in UAE in normoalbuminuric subjects with severe vitamin D deficiency.

Increases in UAE, even within the normoalbuminuric range, constitute a well-known risk factor for adverse cardiovascular outcomes in high-risk individuals [27,28]. More recently, high-normal UAE has become a critical public health issue because high-normal UAE has been associated with the risk of cardiovascular disease and all-cause mortality in the general population [4,5,29]. Additionally, because large-scale, population-based studies have documented a high prevalence of high-normal UAE, ranging from 13% to 23% [30-33], its public health aspects require greater attention. However, despite its significance for public health, there have been few studies investigating its causative or potentially modifiable risk factors, other

| Quartile categories (ng/mL) | Unadjusted | Age-, sex- and season adjusted | Multivariate adjusted* |
|-----------------------------|------------|--------------------------------|------------------------|
| 1st quartile (2.5-14.3), N=3,985 | 1.23 (1.09-1.38) | 1.29 (1.14-1.47) | 1.20 (1.04-1.39) |
| 2nd quartile (14.4-18.8), N=1,632 | 0.98 (0.87-1.12) | 1.12 (0.99-1.28) | 1.11 (0.96-1.29) |
| 3rd quartile (15.9-24.7), N=3,618 | 0.95 (0.83-1.07) | 1.07 (0.94-1.19) | 1.03 (0.89-1.18) |
| 4th quartile (24.8-90.9), N=3,646 | 1.00 | 1.00 | 1.00 |

| Percentile categories (ng/mL) | Unadjusted | Age-, sex- and season adjusted | Multivariate adjusted* |
|-------------------------------|------------|--------------------------------|------------------------|
| 1.0-4.9% (2.5-9.5), N=721 | 1.82 (1.53-2.19) | 1.71 (1.42-2.06) | 1.95 (1.25-1.93) |
| 5.0-24.9% (9.6-14.3), N=2,896 | 1.14 (1.02-1.28) | 1.15 (1.02-1.29) | 1.09 (0.96-1.25) |
| 25.0-49.9% (14.4-18.8), N=3,604 | 1.02 (0.91-1.13) | 1.09 (0.98-1.22) | 1.09 (0.96-1.24) |
| 50.0-100.0% (18.9-90.9), N=7,323 | 1.00 | 1.00 | 1.00 |

| Clinical categories | Unadjusted | Age-, sex- and season adjusted | Multivariate adjusted* |
|---------------------|------------|--------------------------------|------------------------|
| <15 ng/mL, N=4,089 | 1.20 (1.04-1.38) | 1.33 (1.04-1.33) | 1.28 (1.08-1.52) |
| 15.0-29.9 ng/mL, N=8,527 | 0.95 (0.84-1.09) | 1.14 (0.99-1.30) | 1.15 (1.01-1.38) |
| ≥30 ng/mL, N=1,978 | 1.00 | 1.00 | 1.00 |

Figure 4 Odds ratios for high-normal urinary albumin excretion (UACR 10–29 mg/g) as a function of serum 25-hydroxyvitamin D levels by quartile categories (top), percentile categories (middle), and clinical categories (bottom). Black round dots represent odds ratios, and error bars represent the 95% CIs. *Adjusted for age, sex, season, body mass index, hemoglobin, estimated glomerular filtration rate, hypertension, diabetes, use of vitamin D supplements, and/or renin-angiotensin system blocker, serum albumin, calcium, phosphorus, high-density lipoprotein-cholesterol, triglyceride, and high sensitivity-C-reactive protein. UACR, urinary albumin-creatinine ratio.

Figure 5 Predicted prevalence curve for high-normal urinary albumin excretion in subjects with UACR < 30 mg/g (n = 14,594) according to serum 25-hydroxyvitamin D levels. Dashed lines represent 95% CIs. *Adjusted for age, sex, season, body mass index, hemoglobin, estimated glomerular filtration rate, hypertension, diabetes, use of vitamin D supplements, and/or renin-angiotensin system blocker, serum albumin, calcium, phosphorus, high-density lipoprotein-cholesterol, triglyceride, and high sensitivity-C-reactive protein. UACR, urinary albumin-creatinine ratio.
than traditional ones, such as diabetes, hypertension, or obesity. Given that low-grade albuminuria reflects generalized vascular dysfunction via impaired endothelial function, activation of the RAS, and chronic low-grade inflammation [34-37]. conditions relevant to the development of these pathogenic processes could constitute potential risk factors for high-normal UAE. In this respect, vitamin D deficiency is a likely mechanism for the increase in UAE, as it has been shown to play a crucial role in vascular dysfunction. Recent studies have suggested that flow-mediated dilatation, which is a standard tool for measuring endothelial function, was significantly impaired in subjects with vitamin D deficiency [38,39]. Vitamin D deficiency also adversely affected vascular function by inappropriate activation of the RAS [40], and chronic inflammation [41]. These processes might, in turn, increase UAE, even in the absence of evident kidney disease. The data presented show that severe vitamin D deficiency was significantly, but non-linearly, correlated with high-normal UAE, even after adjustment for traditional risk factors for albuminuria. Similar to our results, a previous study found that low serum 25(OH)D levels were associated with an increased prevalence of albuminuria in a general population [14]. However, in that study, microalbuminuria (defined as UACR of 17–249 mg/g for men and 25–354 mg/g for women), but not high-normal UAE, was considered to be a dependent variable, so the reference group included a large number of subjects with high-normal UAE, which is a proven risk factor for adverse outcomes.

Recently, mounting evidence has suggested that the inverse associations between serum 25(OH)D levels and risk factors in cardiovascular outcomes might be non-linear, involving a threshold effect [15,18,19]. Given the close pathophysiological association between albuminuria and cardiovascular disease, serum 25(OH)D levels could also have a threshold effect on levels of UAE. The present results of GAM, which is a non-parametric regression method used to address non-linearity between variables [26], are consistent with the hypothesis that the association between serum 25(OH)D and UACR levels is non-linear. However, the threshold serum 25(OH)D concentration in this study (8 ng/mL) was much lower than that reported in previous studies that explored the associations between serum 25(OH)D levels and risk factors for cardiovascular disease. Previous studies have demonstrated that the risk for cardiovascular disease began to increase significantly at less than 15 to 30 ng/mL of serum 25(OH)D [15,18,19], which is relevant to the current definition of vitamin D deficiency. Considering the high prevalence of vitamin D deficiency in the general population, a substantial number of subjects would be expected to be at vitamin D deficiency-related risk for cardiovascular disease. However, most randomized, controlled trials with vitamin D supplementation have failed to demonstrate improved vascular function or cardiovascular outcomes [42-44], suggesting that low vitamin D levels simply reflect health status, rather than directly causing disease. An alternate explanation for the discrepancy is that vitamin D plays an independent role in the development of cardiovascular disease or vascular dysfunction, when its levels decrease to less than very low levels. This hypothesis was supported by a recent large-scale, population-based study, which demonstrated that only a very low vitamin D level (<5th percentile of serum 25(OH)D) significantly increased the risk of fatal ischemic heart disease after adjustment for traditional cardiovascular risk factors [39]. In accordance with the previous study, the present study also demonstrated that the 25(OH)D threshold levels decreased after adjustment for the traditional cardiovascular risk factors in GAM analysis. Additionally, only the lowest category of serum 25(OH)D was correlated with elevated odds of high-normal UAE after multivariate adjustment. These findings suggest that vitamin D levels related to the pathogenesis of low-grade albuminuria might be lower than the lower limit of the normal range of vitamin D.

There were several limitations to the present study. First, UAE was measured from only a single random urine sample. Individual variability in UACR levels could have caused measurement error for UAE. Second, there was a lack of information on vitamin D dietary intake and outdoor physical activities, which exert effects on vitamin D status. Third, the current investigation was cross-sectionally designed. We could not establish a causative or temporal relationship between vitamin D levels and UAE. Thus, we could not demonstrate whether use of vitamin D could reduce urinary albumin loss in a healthy population with very low degrees of UAE. Finally, the laboratory test methods were not consistent among the institutions. Thus, to combine laboratory test results from different institutions, a normalization process, which transformed different distributions into identical distributions in statistical properties, was indispensable. We used quantile normalization, which is the most widely used normalization method for genetic studies [22]. This method makes the distribution of different datasets as similar as possible while conserving the meaning of original values. To consider the reference range of laboratory tests, we partitioned each datasets into three groups (upper range, within range and below range), and each of them were independently normalized. By
doing this, we could normalize the datasets while con-
serving the clinical meaning and considering the refer-
ence range. Because this method does not assume any
parametric distributions, the method can be applied to
any laboratory test results with various distributions.

Conclusions
Severe vitamin D deficiency was independently associ-
ated with an increased prevalence of high-normal UAE,
which has tended to be overlooked. Based on the clinical
significance of low-grade albuminuria as a predictor of
vascular dysfunction and cardiovascular mortality [4,29],
the clinical implications of severe vitamin D deficiency in
public health as a modifiable risk factor for low-degree
albuminuria might be substantial. We confirmed a non-
linear relationship between vitamin D levels and UAE,
as well as the threshold (8 ng/mL) less than which vita-
m D levels began to be associated with an increase in
UAE. Additional clinical studies are warranted to validate
our study and to evaluate whether vitamin D therapy
could reduce urinary albumin loss in normoalbuminuric
individuals.

Additional file

Additional file 1: Figure S1. Odds ratios for high-normal urinary albumin
excretion (UACR 10–29 mg/g) as a function of serum 25-hydroxyvitamin D
levels by quartile categories (top), percentile categories (middle), and clinical
categories (bottom) in subjects without diabetes and with diabetes. Dashed
lines represent 95% CIs. *Adjusted for age, sex, season, body mass index,
hemoglobin, estimated glomerular filtration rate, hypertension, diabetes,
use of vitamin D supplements, and/or renin-angiotensin system blocker,
serum albumin, calcium, phosphorus, high-density lipoprotein-cholesterol,
triglyceride, and high sensitivity-C-reactive protein. UACR, urinary
albumin-creatinine ratio.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
YJO, RWP, and DKK conceived of the design of this research, and helped to
draft the manuscript. DKK supervised this project. YJO, HRU, HK, HL, NJH, and
SKP collected the data. YJO, DY, MK, and SSH analyzed the data. RWP and
KW supervised the results. YSK and CSL gave conceptual advice and
YJO, RWP, and DKK helped to contribute with their suggestions. KWJ interpreted the results. YSK and CSL gave conceptual advice and
YJO, RWP, and DKK helped to contribute with their suggestions.

Acknowledgements
This work was supported by a grant from the Korean Healthcare Technology
R&D Project, Ministry for Health and Welfare, Republic of Korea (HI10C2020).

Author details
1Department of Internal Medicine, Seoul National University College of
Medicine, 101 Daehak-ro, Jongro-guSeoul 110-744, Korea. 2Department of
Internal Medicine, Cheju Halla General Hospital, Jeju, Korea. 3Center for
Clinical Epidemiology and Biostatistics, and Department of Biostatistics &
Epidemiology and Center for Pharmacoepidemiology Research and Training,
Perelman School of Medicine, University of Pennsylvania, Philadelphia,
Pennsylvania, USA. 4Department of Biomedical Informatics, Ajou University
School of Medicine, Suwon, Korea. 5Department of Dental Hygiene, College
of Health Science, Eulji University, Seongnam, Korea. 6Department of Internal
Medicine, Samsung Medical Center, Sungkyunkwan University School of
Medicine, Seoul, Korea. 7Department of Internal Medicine, University of Ulsan
college of Medicine, Asan Medical Center, Seoul, Korea. 8Department of
Internal Medicine, Healthcare System Gangnam Center, Seoul National
University Hospital, Seoul, Korea.

Received: 21 March 2014 Accepted: 19 June 2014
Published: 24 June 2014

References
1. Kanea WF, Enkoyan G: Proteinuria, albuminuria, risk, assessment,
detection, elimination (PARADE): a position paper of the National Kidney
Foundation. Am J Kidney Dis 1999, 33(5):1004–1010.
2. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G: Urinary protein
excretion rate is the best independent predictor of ESRF in non-diabetic
proteinuric chronic nephropathies. “Gruppo Italiano di Studi Epidemiolo-
gici in Nefropatia” (GISEN). Kidney Int 1998, 53(5):1209–1216.
3. Hillel HLG, Frieder V, Dorcks GF, van Glist WH, de Zeeuw D, van Veldhuisen
DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE: Urinary albumin
excretion predicts cardiovascular and noncardiovascular mortality in general
population. Circulation 2002, 106(14):1777–1782.
4. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong
PE, Coresh J, Garveyvoort RT: Association of estimated glomerular filtration
rate and albuminuria with all-cause and cardiovascular mortality in general
population cohorts: a collaborative meta-analysis. Lancet 2010, 375(9731):2073–2081.
5. Nitsch D, Grams M, Yang S, Black C, Djuric D, Osei K, Kassal SK, Kimm H,
Kronenberg F, Oleen CM, Levey AS, Levin A, Woodward M, Hennelly BM:
Associations of estimated glomerular filtration rate and albuminuria with
mortality and renal failure by sex: a meta-analysis. BMJ 2013, 346:f324.
6. Inker LA, Coresh J, Levey AS, Tonelli M, Muntener P: Estimated GFR,
albuminuria, and complications of chronic kidney disease. J Am Soc
Nephrol 2011, 22(12):2322–2331.
7. Holick MF: Vitamin D deficiency. Am J Med 2007, 357(3):266–281.
8. Iroukai T, Fujikawa Y, Tawara K, Asai Y, Takemura Y: Alterations in serum
levels of alpha,25(OH)2 D3 and osteoclastin in patients with early
idiopathic nephropathy. Diabetes Res Clin Pract 1997, 38(3):53–59.
9. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL:
Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus
in patients with chronic kidney disease: results of the study to evaluate
early kidney disease. Kidney Int 2007, 71(1):31–38.
10. Urena-Torres P, Metzger M, Haymann JP, Karas A, Boffa JJ, Flamment M,
Vrotsoski F, Gauci C, Froissart M, Houllier P, Stengel B: Association of
Kidney Function, Vitamin D Deficiency, and Circulating Markers of
Mineral and Bone Disorders in CKD. Am J Kidney Dis 2011, 58(4):544–553.
11. Isakova T, Gutierrez OM, Patel NM, Andress DL, Wolf M, Levin A: Vitamin D
deficiency, inflammation, and albuminuria in chronic kidney disease: complex
interactions. J Ren Nutr 2011, 21(4):295–302.
12. Ravani P, Malberti F, Tripodi G, Pecchini P, Cutrupi S, Pizzini P, Mallamaci F,
Zoccali C: Vitamin D levels and patient outcome in chronic kidney disease.
Kidney Int 2009, 75(1):88–95.
13. Damasiewicz MJ, Magliano DJ, Daly RM, Gagnon C, Lu ZZ, Sikaris KA,
Ebeling PR, Chadban SJ, Atkins RC, Kerr PG, Shaw JE, Polkinghorne KR:
Serum 25-hydroxyvitamin D deficiency and the 5-year incidence of CKD.
Am J Kidney Dis 2013, 62(1):58–66.
14. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS: 25-Hydroxyvitamin D levels and albuminuria in the Third National
Health and Nutrition Examination Survey (NHANES III). Am J Kidney
Dis 2007, 50(1):69–77.
15. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin
EJ, D’Agostino RB, Wolf M, Vasan RS: Vitamin D deficiency and risk of
cardiovascular disease. Circulation 2010, 117(5):503–511.
16. Malamed ML, Michos ED, Post W, Astor B: 25-hydroxyvitamin D levels and
the risk of mortality in the general population. Arch Intern Med 2008,
168(15):1629–1637.
17. Ashrafi A, Alvarez J, Saenz K, Gower B, McCormick K, Franklin F: Threshold
effects of vitamin D deficiency on glucose metabolism in obese female
African-American adolescents. J Clin Endocrinol Metab 2009, 94(9):3200–3206.
18. Wang L, Song Y, Manson JE, Pilz S, Marz W, Michaelsson K, Ludvigsson K,
Jassal SK, Barrett-Connor E, Zhang C, Eaton CB, May HT, Anderson JL, Sesso
DH, Buring JE, Manson JE, Colditz GA, Willett WC: Vitamin D deficiency
and risk of type 2 diabetes in US women. N Engl J Med 2011, 365(9):829–839.
19. Watanabe K, Ohsaki Y, Arita M, Ishikawa I, Kuwashima M, Torii K, Itsuki
K, Jinnouchi K, Ohnaka K, Imamura F, Oh W, Moriyama Y, Kurihara K,
Kanazawa K, Sasaki S, Tomonaga M, Funatsu S, Sato T, Inoue M, Saito K,
Araki E, Tamakoshi A, Inoue M, Iwamoto M, Kohri H, Tsugane S, Funahashi
T: Vitamin D deficiency and the incidence of type 2 diabetes in middle-aged
Japanese women. Diabetologia 2011, 54(7):1816–1823.
HD. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes 2012, 5(6):819–829.

19. de Boer IH, Levin G, Robinson-Cohen C, Biggs ML, Hoofnagle AN, Siscovick DS, Kestenbaum B. Serum 25-hydroxyvitamin D concentration and risk for major clinical disease events in a community-based population of older adults: a cohort study. Ann Intern Med 2012, 156(9):627–634.

20. Han SS, Kim M, Kim H, Lee SM, Oh YJ, Lee JP, Kim S, Joo KW, Lim CS, Kim SY, Kim DK. Non-Linear Relationship between Serum 25-Hydroxyvitamin D and Hemoglobin in Korean Females: The Korean National Health and Nutrition Examination Survey 2010–2011. PLoS One 2013, 8(8):e72605.

21. Skaaby T, Husmoen LL, Pisinger C, Jorgensen T, Thuesen BH, Rasmussen K, Fenger M, Rossing P, Linneberg A. Vitamin D status and 5-year changes in urine albumin creatinine ratio and parathryoid hormone in a general population. Endocrine 2013, 44(2):473–480.

22. Bolstad BM, Irzany RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19(12):185–193.

23. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003, 42(4 Suppl 3):S51–S201.

24. Mehrotra R, Kermah DA, Salusky IB, Wolf MS, Thadhani R, Chu YW, Martins D, Adler SG, Norris KC. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int 2009, 76(2):977–983.

25. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kestenbaum B, Ahrens Jr WH, Van Lente F. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006, 145(4):247–254.

26. Hastei T, Tibshirani R. Exploring the nature of covariate effects in the proportional hazards model. Biometrics 1990, 46(4):1005–1016.

27. Wachtl K, Ibsen H, Olsen MH, Borh-Johnsen K, Lindholm LH, Mogensen CE, Dahløf B, Devereux RB, Beavers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansen K, Køber-Lidegaard P, Nielsen MB, Olsen JM, Omvik P, Opasich S, Pedersen HE, Petterson A, Pfeiffer AF, Podrid PJ, Prospective Atherosclerosis Risk in Communities Study Investigators, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003, 139(11):901–906.

28. Gerstein HC, Mann JF, Yi Q, Zimmet P, Cooper RS, Hoi S, Huxley R, et al. Low-grade albuminuria and incidence of cardiovascular disease events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286(4):431–426.

29. Arnljot J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D’Agostino RB, Vasan RS. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005, 112(7):969–975.

30. Astor BC, Hallan SI, Miller ER, 3rd, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 2008, 167(10):1226–1234.

31. Matsuura K, Selvin E, Bush D, Astor BC, Coresh J. Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2010, 55(4):648–659.

32. White SL, Polkinghome KR, Atkins RC, Chadbourn SJ. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. Am J Kidney Dis 2010, 55(4):660–670.

33. Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, Graham A, Moy CS, Howard G. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology 2005, 25(3):135–143.

34. Deckert T, Feldt-Rasmussen B, Borh-Johnsen K, Jensen T, Kofod-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989, 32(4):219–226.

35. Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. J Am Soc Nephrol 2006, 17(8):2106–2111.

36. Al Mheid I, Patel R, Munrow J, Morris A, Rahman A, Fike L, Kavtaradze N, Uphoff V, Hooper C, Tantraphicha V, Alexander RW, Brigham K, Quyyumi AA. Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J Am Coll Cardiol 2011, 58(2):186–192.

37. Brondum-Jacobsen P, Benn M, Jensen GB, Nordestgaard BG. 25-hydroxyvitamin D levels and risk of ischemic heart disease, myocardial infarction, and early death: population-based study and meta-analyses of 18 and 17 studies. Atherosclerosis Thromb Vasc Biol 2012, 32(11):2794–2802.

38. Li YC, Kong J, Wei M, Chen ZT, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002, 110(2):229–238.

39. Rigby WF, Denome S, Fanger MW. Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J Clin Invest 1987, 79(6):1659–1664.

40. Gepner AD, Ramarramuthy R, Krueger DC, Korczak CE, Binkey N, Stein JH. A prospective randomized controlled trial of the effects of vitamin D supplementation on cardiovascular disease risk. PLoS One 2012, 7(5):e36617.

41. Whatham MD, Dove FJ, Khan F, Lang CC, Belch JJ, Strattons AD. Effects of Vitamin D supplementation on markers of vascular function after myocardial infarction–a randomised controlled trial. Int J Cardiol 2013, 167(3):745–749.

42. Wood AD, Seembrace KR, Thies F, Aucott L, Black AJ, Mavrodi N, Simpson WG, Fraser WD, Reid DM, Macdonald HM. Vitamin D3 supplementation has no effect on conventional cardiovascular risk factors: a parallel-group, double-blind, placebo-controlled RCT. J Clin Endocrinol Metab 2012, 97(10):3557–3568.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Visit www.biomedcentral.com/submit to submit your manuscript today.